Pope Francis holds historic meeting with Iraq's top Shia cleric    Egypt reports 579 new coronavirus cases; 45 deaths on Friday    61st Diyarna Exhibition: Showcasing Egyptian Handicrafts    Art House partners with Cultural Development Fund to present theatrical, musical shows    Egypt stresses necessity of launching 'serious' negotiation process to reach deal on GERD before flood season    Ethiopia says AU-led GERD negotiations will be win-win, expects close agreement    Arab interests must be voiced unanimously to reflect unified will: Aboul Gheit    Egypt, Jordan, and Palestine reiterate call for halting Israeli settlement activities    International Cooperation Ministry, AfDB sign development financing of €109m for rural Luxor sanitation services    Egypt, Sudan finalise agreement strengthening military cooperation    Yemen's Houthis fire missile at Saudi Aramco site in Jeddah    Messi serves as bright spot in Barcelona's disastrous season    Zamalek ready with striking force against Esperance Tunis    Egypt clubs protest Football Association decision to cover costs of COVID-19 tests    Egypt on transformational path into regional energy trade centre: Petroleum Minister    Egypt's National Council for Women launches awareness campaign on nutrition education    Planning Ministry prioritises Upper Egypt development under coherent, integrated programme    Al-Sisi, Guinea-Bissau counterpart discuss counterterrorism, GERD negotiations    Hassan Allam wins contract to manage, operate Grand Egyptian Museum    March: The month of celebrating women    Egypt launches ‘Closing the Gender Gap Accelerator' action plan    Africa welcomes COVAX doses but warns against 'selfishness'    Preview: Ahly seeking to dispel doubts in CL clash against Vita Club    Preview: Zamalek hoping to maintain recent dominance over Tunisia's Esperance    Pope urges Iraqis to shun past violence and give peace a chance    Egyptian Journalists' Syndicate midterm elections postponed to 19 March    UPDATED: Pope Francis arrives in Baghdad for risky, historic Iraq tour    Juve face Lazio test before crunch Champions League game    Moody's completes periodic review of ratings of GIG Insurance – Egypt    Sudan keen to enhance cooperation with Egypt: Sudanese FM Al-Mahdi    Egypt improves ranking on Heritage Foundation's Index of Economic Freedom    A Happy Purrfect Rescue Story of 4 Cats in Thailand    Egypt court upholds 3-year prison sentence for Mubarak-era Minister El-Feky    Spotify competitor Anghami to become first Arab tech firm to list on Nasdaq, eyes plans for Egypt    Egypt's Zamalek arrive in Tunisia to face Esperance in CAF Champions League    Winston Churchill's Moroccan landscape painting owned by Angelina Jolie sells for $11.5M    Syrian pound hits new low in contagion from neighboring Lebanon's currency crisis    Orascom Construction to build Magdi Yacoub Global Heart Centre    Respect for diversity    From the trading floor    Huawei launches HUAWEI FreeLace Pro in Egypt with extra-long battery life and top-grade noise cancellation    Enhanced Labs signs Mr. Olympia 2020 "Big Ramy" And His Trainer Dennis James    1st hours of registration for coronavirus vaccine seen 7,000 Egyptians signing up: ministry    King Tutankhamun funerary mask is must-see tourist icon: The Telegraph    Egypt eyes gradual return for tourism after revenues fall to $4 bln in 2020    Seasoned Egyptian screenwriter Wahid Hamed dies at 76    Coronavirus strikes Egypt's youth team as 17 players, coach test positive    Egypt, Ethiopia, Sudan to resume Nile dam talks today    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.





BioNTech, Pfizer testing potential coronavirus vaccine, could “supply millions” by year-end
Published in Amwal Al Ghad on 30 - 04 - 2020

German drugmaker BioNTech and U.S. pharmaceutical giant Pfizer have begun human trials of a potential coronavirus vaccine that could supply millions by the end of the year, the two firms said on Wednesday.
From its part, Pfizer said it would begin testing its experimental vaccine in the United States as early as next week, adding that a vaccine could be ready for emergency use in the fall, the Wall Street Journal reported on Tuesday.
BioNTech said the first cohort of participants had been given doses of the potential vaccine, BNT162, in a Phase 1/2 clinical study in Germany.
"Twelve study participants have been vaccinated with the vaccine candidate BNT162 in Germany since the start of the study on April 23, 2020,” the company said in a statement.
BioNTech said around 200 healthy volunteers aged between 18 to 55 years old would be given doses ranging from 1µg (microgram) to 100µg to find the optimal dose for further studies.
“In addition, the safety and immunogenicity of the vaccine will be investigated,” noted the German biotech company.
Pfizer and BioNTech plan to initiate trials for BNT162 in the U.S. on regulatory approval, expected shortly, the joint statement read.
The German Federal Institute for Vaccines and Biomedical Drugs has given the green light for the trial — the country's first clinical experiment for a vaccine against coronavirus on April 22.
“The two companies plan to jointly conduct clinical trials for the COVID-19 vaccine candidates initially in Europe and the U.S., across multiple research sites,” Pfizer announced in its first quarter report, released online on Tuesday.
“Pfizer and BioNTech also plan to conduct trials for BNT162 in the U.S. upon regulatory approval, which is expected shortly,” the report said.
“The companies estimate that there is potential to supply millions of vaccine doses by the end of 2020, subject to technical success of the development program and approval by regulatory authorities, and the potential to rapidly scale up the capacity to produce hundreds of millions of doses in 2021.”


Clic here to read the story from its source.